As of November 6, 2026, PTC Therapeutics, Inc. is a publicly traded company (Nasdaq: PTCT); its largest reported holder is BlackRock, with 14.8% on Schedule 13G/A of December 4, 2025, then Janus Henderson (8.7%). The largest insider holding is Michael Schmertzler, a director, with 1,454,860 shares (1.7% of shares outstanding), per Form 4 of October 16, 2026 (Schedule 13G/A, December 4, 2025).
Is this your company?
About to sign with, pay or invest in PTC Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is PTC Therapeutics, Inc. a real, registered company?
- Ptc Therapeutics, Inc. files with the SEC under CIK 1070081 (its SEC filings).
- Its shares are listed under the ticker PTCT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Warren, New Jersey, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under PTC THERAPEUTICS, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Alethia Young, Director (Form 8-K filed 2026-06-09). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Janus Henderson (filed 2026-05-15).
Who are PTC Therapeutics, Inc.'s owners and officers?
PTC Therapeutics, Inc.: incorporated in Delaware; business address in Warren, New Jersey; industry Pharmaceutical Preparations (Form D, 2026-06-09).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2023-05-08)
- : Executive Officer (Form D, 2023-05-08)
- : Executive Officer (Form D, 2023-05-08)
- : Executive Officer (Form D, 2023-05-08)
- : Executive Officer (Form D, 2023-05-08)
- : Executive Officer (Form D, 2023-05-08)
- : Director (Form D, 2023-05-08)
- : Director (Form D, 2023-05-08)
- : Director (Form D, 2023-05-08)
- : Director (Form D, 2023-05-08)
- : Director (Form D, 2023-05-08)
- : Director (Form D, 2023-05-08)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-05-15 | Janus Henderson Group PLC | 8.7% |
| Schedule 13G/A, 2026-05-15 | The Toronto-Dominion Bank | 3.7% |
| Schedule 13G, 2026-04-30 | Vanguard Capital Management | 5.17% |
| Schedule 13G, 2026-04-29 | Vanguard Portfolio Management | 5.88% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G, 2026-02-17 | Janus Henderson Group PLC | 6% |
| Schedule 13G, 2026-02-13 | The Toronto-Dominion Bank | 5.2% |
| Schedule 13G/A, 2026-02-10 | Wellington Management Group LLP | 4.8% |
| Schedule 13G, 2026-02-09 | State Street Corporation | 5.2% |
| Schedule 13G/A, 2025-12-04 | Blackrock, Inc. | 14.8% |
| Schedule 13G/A, 2025-11-14 | Armistice Capital, LLC | 4.08% |
| Schedule 13G/A, 2025-10-30 | The Vanguard Group | 10.43% |
Questions about who owns PTC Therapeutics, Inc.
Who owns PTC Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of PTC Therapeutics, Inc.: Blackrock, Inc. (14.8%, Schedule 13G/A, filed 2025-12-04), Janus Henderson Group PLC (8.7%, Schedule 13G/A, filed 2026-05-15), Vanguard Portfolio Management (5.88%, Schedule 13G, filed 2026-04-29), State Street Corporation (5.2%, Schedule 13G, filed 2026-02-09) and Vanguard Capital Management (5.17%, Schedule 13G, filed 2026-04-30).
Who are the largest shareholders of PTC Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of PTC Therapeutics, Inc. on this page are Blackrock, Inc. (14.8%), Janus Henderson Group PLC (8.7%) and Vanguard Portfolio Management (5.88%).
When did Blackrock, Inc. buy into PTC Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Blackrock, Inc. on this page is the Schedule 13G/A, filed 2025-12-04, reporting 14.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on PTC Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on PTC Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on PTC Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-09 | Alethia Young | Director | departed | 2026-06-08 |
Which insiders own PTC Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 1,454,860 shares (1.7% of shares outstanding), 163,266 held directly and 1,291,594 indirectly (Form 4, 2026-10-16).
- , M.D., the chief executive and a director: 383,868 shares (0.46% of shares outstanding) (Form 4, 2026-08-06).
- , the executive vice president and chief legal officer: 105,272 shares (0.13% of shares outstanding) (Form 4, 2026-10-13).
- , the chief financial officer: 83,986 shares (0.10% of shares outstanding) (Form 4, 2026-07-16).
- , the executive vice president and chief medical officer: 79,115 shares (0.09% of shares outstanding) (Form 4, 2026-04-06).
Shares outstanding: 83,544,284 as of 2026-10-27, from the company's latest SEC cover page.
How much has PTC Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2023-05-08 | $35.90M | $35.90M |
Keep reading
More on PTC Therapeutics, Inc. and the records around it.
PTC Therapeutics, Inc. elsewhere on the record
- Leadership changes Jul 2026
- 5%+ stake filings May 2026
Companies that share a holder
- The Toronto-Dominion Bank also filed stake reports on 5 other companies: eBay Inc. (Aug 2026), Stoke Therapeutics, Inc. (Aug 2026), UroGen Pharma Ltd. (Aug 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/ptc-therapeutics